Onconetix, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $815,371 | $2.5M | $5,963 | — | — |
| Cost of revenue | $182,458 | $1.5M | $1.2M | — | — |
| Gross profit | $632,913 | $1.1M | -$1.1M | — | — |
| Selling, general & administrative | $7.0M | $11.2M | $14.8M | $9.4M | — |
| Research and development | — | $154,359 | $1.9M | $4.1M | $1.3M |
| Operating expenses | $18.5M | $57.5M | $34.9M | $13.5M | $3.4M |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M |
| Interest expense | $751,005 | $873,433 | $671,625 | — | — |
| Pretax income | -$14.0M | -$59.7M | -$37.4M | -$13.4M | — |
| Income tax expense | $525 | -$1.0M | -$12,593 | $3.2T | $675.7B |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | — | $25.8M | $1.9M |
| Current assets | $6.1M | $950,267 | $5.8M | $26.3M | $3.1M |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M |
| Current liabilities | $9.1M | $18.3M | $17.2M | $3.9M | $1.6M |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M |
| Stockholders' equity | $15.8M | $8.5M | -$5.6M | $22.4M | $1.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Depreciation and amortization | $15,000 | $22,000 | $43,937 | $6,752 | $4,890 |
| Stock-based compensation | $74,267 | $438,653 | $329,760 | $2.0M | $130,141 |
| Capital expenditure | — | $28,471 | $3,300 | $9,339 | $1,924 |
| Free cash flow | — | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Share repurchases | — | $59,000 | — | $566,810 | — |
| Impairments | $11.5M | $3.5M | $14.7M | — | — |
Shares outstanding 11.5M · Free float 5.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.